FDA Launches New Infectious Diseases App

it will allow health care providers, others to report experience with off-label treatment
Robert Calandra

The FDA has launched an app called CURE ID that will allow medical professionals to report their experiences with difficult-to-treat infectious diseases with novel uses of FDA-approved drugs.

The repository is collaboration between the FDA and the National Center for Advancing Translational Sciences (NCATS), which is part of the National Institutes of Health (NIH).

The app can be accessed via a website, smartphone, or other mobile device. The app will enable crowdsourcing of medical information from health care providers worldwide to guide potentially life-saving interventions and lead to the development of new drugs for neglected diseases.

“The CURE ID application focuses on drugs for infectious diseases lacking adequate treatments, including neglected tropical diseases, emerging infectious threats and infections caused by antimicrobial-resistant organisms,” said Amy Abernethy, MD, the FDA principal deputy commissioner. “Our hope is that this app will serve as a connector among major treatment centers, academics, private practitioners, government facilities and other health care professionals from around the world and ultimately get treatments to patients faster.”  

The app works by collecting a simple case report from caregivers about their experience using an approved product for an unapproved use.

CURE ID captures the clinical outcomes when drugs are used for new indications, in new populations, in new doses or in new combinations. Medical professionals can then browse the collected cases.

The systematic collection of real-world experience in the app will help identify drug candidates for additional study, encourage further drug development, and may serve as a resource for practitioners making individual patient treatment decisions in the absence of established safe and effective options.